Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Metopimazine

Metopimazine Am J Cancer 2006; 5 (2): 123-136 ADIS DRUG EVALUATION 1175-6357/06/0002-0123/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. A Review of its Use in the Treatment of Chemotherapy-Induced Nausea and Vomiting Katherine F. Croom and Gillian M. Keating Adis International Inc, Yardley, Pennsylvania, USA Various sections of the manuscript reviewed by: E. Ballatori, Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy; M. Di Palma, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; L. Dupuis, Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada; J. Herrstedt, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark; K. Jordan, Klinik fur ¨ Innere Medizin IV, Universitatsklinik Halle/Wittenberg, Halle, Germany; ¨ J.-E. Kurtz, Departement d’H ´ ematologie et d’Oncologie, ´ Hopitaux Universitaires de Strasbourg, Strasbourg, France; ˆ H. Link, Medizinische Klinik I, Westpfalz-Klinikum, Kaiserslautern, Germany; I. Olver, Department of Cancer Care, University of Adelaide, Adelaide, South Australia, Australia; P.J. Souquet, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite Cedex, France; G. Tonini, Oncology Department, Campus Bio-Medico University, Rome, Italy; S. Van Belle, Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium. Data Selection Sources: Medical literature published in any language since 1980 on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Metopimazine

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/metopimazine-hpQfOpJTWn
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605020-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (2): 123-136 ADIS DRUG EVALUATION 1175-6357/06/0002-0123/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. A Review of its Use in the Treatment of Chemotherapy-Induced Nausea and Vomiting Katherine F. Croom and Gillian M. Keating Adis International Inc, Yardley, Pennsylvania, USA Various sections of the manuscript reviewed by: E. Ballatori, Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy; M. Di Palma, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; L. Dupuis, Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada; J. Herrstedt, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark; K. Jordan, Klinik fur ¨ Innere Medizin IV, Universitatsklinik Halle/Wittenberg, Halle, Germany; ¨ J.-E. Kurtz, Departement d’H ´ ematologie et d’Oncologie, ´ Hopitaux Universitaires de Strasbourg, Strasbourg, France; ˆ H. Link, Medizinische Klinik I, Westpfalz-Klinikum, Kaiserslautern, Germany; I. Olver, Department of Cancer Care, University of Adelaide, Adelaide, South Australia, Australia; P.J. Souquet, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite Cedex, France; G. Tonini, Oncology Department, Campus Bio-Medico University, Rome, Italy; S. Van Belle, Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium. Data Selection Sources: Medical literature published in any language since 1980 on

Journal

American Journal of Cancer – Springer Journals

Published: Aug 9, 2012

References

  • Understanding the pathobiology of chemotherapy-induced nausea and vomiting: providing a basis for therapeutic progress
    Hesketh, P.J.
  • ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)
    Herrstedt, J.; Aapro, M.S.; Roila, F.
  • Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment
    Jordan, K.; Kasper, C.; Schmoll, H.-J.
  • Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
    Kris, M.G.; Hesketh, P.J.; Herrstedt, J.
  • Delayed emesis: moderately emetogenic chemotherapy
    Roila, F.; Warr, D.; Clark-Snow, R.A.
  • Acute emesis: moderately emetogenic chemotherapy
    Herrstedt, J.; Koeller, J.M.; Roila, F.
  • Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and (α1-adrenergic receptors
    Herrstedt, J.; Hyttel, J.; Pedersen, J.
  • Cancer: principles and practice of oncology
    Berger, A.; Clark-Snow, R.A.
  • The effect of food on serum concentrations of metopimazine
    Herrstedt, J.; Jorgensen, M.; Angelo, H.R.
  • Bioavailability of the antiemetic metopimazine given as a microenema
    Herrstedt, J.; Jorgensen, M.; Angelo, H.R.
  • Controlled studies of metopimazine for the treatment of nausea and vomiting
    Moertel, C.G.; Reitemeier, R.J.
  • Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: results of two controlled studies
    Israel, L.; Rodary, C.
  • A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis
    Bethune-Volters, A.; Chidiac, J.; Bensaoula, O.
  • Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy
    Sigsgaard, T.; Herrstedt, J.; Handberg, J.
  • Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy
    Herrstedt, J.; Sigsgaard, T.; Boesgaard, M.
  • Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
    Sigsgaard, T.; Herrstedt, J.; Andersen, L.J.
  • Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer
    Herrstedt, J.; Sigsgaard, T.; Handberg, J.
  • The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy
    Lebeau, B.; Depierre, A.; Giovannini, M.
  • Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy
    Bloch, J.; Rixe, O.; Meric, J.B.
  • Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: an update
    Grunberg, S.M.; Osoba, D.; Hesketh, P.J.
  • Proposal for classifying the acute emetogenicity of cancer chemotherapy
    Hesketh, P.J.; Kris, M.G.; Grunberg, S.M.
  • Antiemetic effects of ondansetron and metopimazine [reply]
    Herrstedt, J.; Sigsgaard, T.; Dombernowsky, P.
  • Dose-finding study of oral metopimazine
    Herrstedt, J.; Sigsgaard, T.; Angelo, H.R.
  • Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
    Hesketh, P.J.; Belle, S.; Aapro, M.
  • Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting
    Dando, T.M.; Perry, C.M.
  • Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis
  • Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breats cancer after moderately emetogenic chemotherapy
    Warr, D.G.; Hesketh, P.J.; Gralla, R.J.
  • A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis
    Olver, I.; Paska, W.; Depierre, A.
  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonestron with ondansetron
    Gralla, R.; Lichinitser, M.; Vegt, S.
  • Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3receptor antagonist
    Eisenberg, P.; Figueroa-Vadillo, J.; Zamora, R.
  • Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine
    Herrstedt, J.